Overview Dividends

(WVE) Wave Life Sciences - Ratings and Ratios

Exchange: NASDAQ • Country: Singapore • Currency: USD • Type: Common Stock • ISIN: SG9999014716

RNA Editing, GalNAc-Conjugated siRNA, Exon Skipping, Allele-Selective

WVE EPS (Earnings per Share)

EPS (Earnings per Share) of WVE over the last years for every Quarter: "2020-09": -0.86, "2020-12": -0.59, "2021-03": -0.86, "2021-06": -0.78, "2021-09": -0.12, "2021-12": -0.61, "2022-03": -0.62, "2022-06": -0.62, "2022-09": -0.42, "2022-12": -0.47, "2023-03": -0.27, "2023-06": -0.2, "2023-09": 0.07, "2023-12": -0.15, "2024-03": -0.24, "2024-06": -0.25, "2024-09": -0.466, "2024-12": 0.17, "2025-03": -0.29, "2025-06": -0.31, "2025-09": 0,
EPS Growth (3Y CAGR): 198.23%
EPS Trend (3Y Correlation): 23.8%

WVE Revenue

Revenue of WVE over the last years for every Quarter: 2020-09: 3.45, 2020-12: 9.439, 2021-03: 9.439, 2021-06: 2.776, 2021-09: 36.423, 2021-12: 1.765, 2022-03: 1.75, 2022-06: 0.375, 2022-09: 0.285, 2022-12: 1.239, 2023-03: 12.929, 2023-06: 22.106, 2023-09: 49.214, 2023-12: 29.056, 2024-03: 12.538, 2024-06: 19.692, 2024-09: -7.676, 2024-12: 83.748, 2025-03: 9.175, 2025-06: 8.699, 2025-09: null,
Revenue Growth (3Y CAGR): 246.63%
Revenue Trend (3Y Correlation): 12.8%
Risk via 10d forecast
Volatility 81.9%
Value at Risk 5%th 117%
Relative Tail Risk -12.92%
Reward TTM
Sharpe Ratio -0.81
Alpha -72.78
Character TTM
Hurst Exponent 0.586
Beta 1.349
Beta Downside 2.049
Drawdowns 3y
Max DD 66.67%
Mean DD 31.88%
Median DD 32.60%

Description: WVE Wave Life Sciences November 12, 2025

Wave Life Sciences Ltd. (NASDAQ: WVE) is a Singapore-based, clinical-stage biotech that builds RNA-based medicines using its proprietary PRISM platform, which integrates multiple oligonucleotide chemistries, genetic insight, and modality flexibility to target both rare and common diseases.

The current pipeline includes: WVE-006 (RNA-editing for alpha-1 antitrypsin deficiency), WVE-007 (GalNAc-conjugated siRNA aimed at INHBE for obesity), WVE-N531 (exon-skipping for Duchenne muscular dystrophy), and WVE-003 (allele-selective oligonucleotide for Huntington’s disease). The company leverages strategic collaborations with GlaxoSmithKline, Takeda, and Asuragen, which provide milestone-based funding and potential co-commercialization rights. As of the most recent filing (Q3 2024), Wave reported approximately $150 million of cash and marketable securities, giving it roughly 18 months of runway at current burn rates-a key KPI for assessing near-term financing risk. The broader RNA-therapeutics sector is expanding at a compound annual growth rate of ~12 % (2023-2028), driven by advances in delivery technologies and increasing acceptance of nucleic-acid drugs, which underpins the market opportunity for Wave’s platform.

If you’re looking for a data-rich, quantitative assessment of Wave’s valuation and risk profile, a deeper dive into ValueRay’s analyst dossier may be a useful next step.

WVE Stock Overview

Market Cap in USD 1,252m
Sub-Industry Pharmaceuticals
IPO / Inception 2015-11-11
Return 12m vs S&P 500 -58.8%
Analyst Rating 4.62 of 5

WVE Dividends

Currently no dividends paid

WVE Growth Ratios

CAGR 3y 21.18%
CAGR/Max DD Calmar Ratio 0.32
CAGR/Mean DD Pain Ratio 0.66
Current Volume 2323.9k
Average Volume 2532.4k

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-129.9m TTM) > 0 and > 6% of Revenue (6% = 5.64m TTM)
FCFTA -0.79 (>2.0%) and ΔFCFTA -17.23pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 144.9% (prev -0.95%; Δ 145.9pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.79 (>3.0%) and CFO -199.2m <= Net Income -129.9m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 2.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (164.0m) change vs 12m ago 26.60% (target <= -2.0% for YES)
Gross Margin 23.09% (prev 92.04%; Δ -68.95pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 40.74% (prev 52.92%; Δ -12.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -10.52 (EBITDA TTM -134.8m / Interest Expense TTM -13.6m) >= 6 (WARN >= 3)

Altman Z'' -16.68

(A) 0.54 = (Total Current Assets 223.6m - Total Current Liabilities 87.4m) / Total Assets 252.4m
(B) -4.83 = Retained Earnings (Balance) -1.22b / Total Assets 252.4m
warn (B) unusual magnitude: -4.83 — check mapping/units
(C) -0.62 = EBIT TTM -143.5m / Avg Total Assets 230.6m
(D) -0.27 = Book Value of Equity -28.3m / Total Liabilities 105.2m
Total Rating: -16.68 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 31.30

1. Piotroski 0.50pt = -4.50
2. FCF Yield -18.79% = -5.0
3. FCF Margin data missing
4. Debt/Equity 0.15 = 2.49
5. Debt/Ebitda 1.39 = 1.16
6. ROIC - WACC (= -97.72)% = -12.50
7. RoE -74.89% = -2.50
8. Rev. Trend 12.77% = 0.96
9. EPS Trend 23.78% = 1.19

What is the price of WVE shares?

As of November 15, 2025, the stock is trading at USD 7.08 with a total of 2,323,923 shares traded.
Over the past week, the price has changed by -9.92%, over one month by -10.27%, over three months by -20.54% and over the past year by -52.80%.

Is Wave Life Sciences a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Wave Life Sciences (NASDAQ:WVE) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 31.30 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of WVE is around 6.16 USD . This means that WVE is currently overvalued and has a potential downside of -12.99%.

Is WVE a buy, sell or hold?

Wave Life Sciences has received a consensus analysts rating of 4.62. Therefore, it is recommended to buy WVE.
  • Strong Buy: 9
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the WVE price?

Issuer Target Up/Down from current
Wallstreet Target Price 19.8 179.7%
Analysts Target Price 19.8 179.7%
ValueRay Target Price 7 -0.7%

WVE Fundamental Data Overview November 11, 2025

Market Cap USD = 1.25b (1.25b USD * 1.0 USD.USD)
P/S = 13.3217
P/B = 8.0262
Beta = -1.739
Revenue TTM = 93.9m USD
EBIT TTM = -143.5m USD
EBITDA TTM = -134.8m USD
Long Term Debt = 21.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 16.3m USD (from shortTermDebt, last quarter)
Debt = 21.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -186.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.06b USD (1.25b + Debt 21.7m - CCE 208.5m)
Interest Coverage Ratio = -10.52 (Ebit TTM -143.5m / Interest Expense TTM -13.6m)
FCF Yield = -18.79% (FCF TTM -200.1m / Enterprise Value 1.06b)
FCF Margin = -213.0% (FCF TTM -200.1m / Revenue TTM 93.9m)
Net Margin = -138.2% (Net Income TTM -129.9m / Revenue TTM 93.9m)
Gross Margin = 23.09% ((Revenue TTM 93.9m - Cost of Revenue TTM 72.2m) / Revenue TTM)
Gross Margin QoQ = 74.76% (prev 76.41%)
Tobins Q-Ratio = 4.22 (Enterprise Value 1.06b / Total Assets 252.4m)
Interest Expense / Debt = 13.27% (Interest Expense 2.88m / Debt 21.7m)
Taxrate = -0.0% (0.0 / -50.5m)
NOPAT = -143.5m (EBIT -143.5m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 2.56 (Total Current Assets 223.6m / Total Current Liabilities 87.4m)
Debt / Equity = 0.15 (Debt 21.7m / totalStockholderEquity, last quarter 147.1m)
Debt / EBITDA = 1.39 (negative EBITDA) (Net Debt -186.8m / EBITDA -134.8m)
Debt / FCF = 0.93 (negative FCF - burning cash) (Net Debt -186.8m / FCF TTM -200.1m)
Total Stockholder Equity = 173.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -51.46% (Net Income -129.9m / Total Assets 252.4m)
RoE = -74.89% (Net Income TTM -129.9m / Total Stockholder Equity 173.4m)
RoCE = -73.54% (EBIT -143.5m / Capital Employed (Equity 173.4m + L.T.Debt 21.7m))
RoIC = -86.68% (negative operating profit) (NOPAT -143.5m / Invested Capital 165.6m)
WACC = 11.04% (E(1.25b)/V(1.27b) * Re(11.0%) + D(21.7m)/V(1.27b) * Rd(13.27%) * (1-Tc(-0.0)))
Discount Rate = 11.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 22.31%
Fair Price DCF = unknown (Cash Flow -200.1m)
EPS Correlation: 23.78 | EPS CAGR: 198.2% | SUE: 1.47 | # QB: 1
Revenue Correlation: 12.77 | Revenue CAGR: 246.6% | SUE: -0.04 | # QB: 0

Additional Sources for WVE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle